Ipamorelin and CJC-1295 were removed from the FDA's Category 2 restricted compounding list in September 2024. They are legally compoundable by licensed 503A pharmacies today. Most longevity clinics that offer them have no content strategy around them — and most clinics that do not offer them do not know they can. Here is how to build patient acquisition around the two most marketable growth hormone secretagogues available right now.
What ipamorelin and CJC-1295 are
Ipamorelin is a growth hormone secretagogue — a compound that stimulates the pituitary gland to secrete growth hormone. It acts on the ghrelin receptor (GHS-R1a) and is classified as a growth hormone-releasing peptide (GHRP). Consisting of five amino acids with a half-life of approximately 2 hours, ipamorelin is notable for its selectivity: it stimulates GH release with minimal effect on cortisol or prolactin, which are common side-effect drivers with less selective compounds like GHRP-2 and GHRP-6.
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. The version without DAC (drug affinity complex) — also called Modified GRF 1-29 — has a half-life of approximately 30 minutes and is the version that was removed from Category 2 in September 2024. The version with DAC uses albumin binding to extend the half-life to 6 to 8 days, allowing less frequent dosing but operating under different regulatory considerations. Confirm with your compounding pharmacy which version they produce before making any marketing claims about dosing frequency or protocol structure.
The combination of ipamorelin and CJC-1295 (without DAC) is one of the most commonly prescribed stacks in longevity medicine. CJC-1295 extends the GH release pulse; ipamorelin amplifies the pituitary response via a complementary receptor pathway. Together, they produce a more sustained and pronounced GH secretion pattern than either compound alone — which is why the stack is consistently more popular in clinical practice than either peptide in isolation.
The regulatory status: why these compounds are different from BPC-157
Ipamorelin and CJC-1295 (without DAC) were placed on the FDA's Category 2 list in October 2023 alongside 17 other peptides. In September 2024, the FDA removed them from Category 2 — not because of formal regulatory approval, but because the nominators who had petitioned for the safety review withdrew their submissions. That withdrawal returned these compounds to a status where 503A compounding pharmacies can produce them legally under physician prescription.
This is a meaningfully different position than BPC-157, TB-500, and the other 12 compounds that remain in Category 2 pending the July 23–24, 2026 PCAC ruling. Clinics do not need to wait for any upcoming regulatory event to offer ipamorelin or CJC-1295. They can compound and prescribe them today.
Who is the ipamorelin and CJC-1295 patient
The patient population for these compounds spans multiple clinic specialties and is wider than most peptide content currently serves:
- Men 35–55 seeking body composition optimization. Growth hormone declines approximately 14% per decade after age 30 in men. Patients experiencing changes in body composition — increased fat accumulation, difficulty maintaining muscle despite consistent training — are natural candidates for GH secretagogue protocols.
- Women in perimenopause and menopause. GH decline is equally significant in women during hormonal transition. This patient segment is substantially underserved by existing peptide content, where the overwhelming majority of material is written for men.
- Longevity patients seeking comprehensive protocols. Patients already engaged in hormone optimization, NAD+ infusions, or other longevity interventions are natural candidates to add GH secretagogue support to their regimen.
- Recreational athletes seeking recovery support. Note that ipamorelin is listed as a prohibited substance on the WADA 2025 Prohibited List under Growth Hormone Releasing Peptides. Clinics marketing to competitive athletes should disclose this clearly. For recreational fitness patients without competition obligations, recovery framing is appropriate.
How to position ipamorelin and CJC-1295 in your marketing
The "available now" positioning
Most peptide content focuses on compounds still in regulatory limbo — BPC-157, TB-500, MOTS-c. The fact that ipamorelin and CJC-1295 are available today through licensed channels is genuinely differentiated. A clinic page that leads with "these compounds are legally compoundable today, without waiting for the PCAC ruling" addresses the regulatory anxiety that every informed peptide patient carries. It is also true — and that accuracy is the foundation of trust.
The GH optimization protocol framing
Growth hormone secretagogue therapy is a distinct and established category within anti-aging medicine. Framing ipamorelin and CJC-1295 within that category — rather than as "peptides" broadly — allows you to speak to the substantial patient population seeking GH optimization who may not identify as peptide patients at all. They may have searched "growth hormone therapy" or "anti-aging hormone clinic" before ever discovering peptides specifically.
The comparison with sermorelin and exogenous HGH
Patients who have researched sermorelin or seen content about growth hormone therapy will search for comparisons. A page that clearly explains how ipamorelin and CJC-1295 differ from sermorelin (different receptor pathways, commonly stacked) and from exogenous HGH (working with the pituitary rather than replacing it) captures high-intent comparison traffic from patients already close to a booking decision.
Comparison: ipamorelin, CJC-1295, and sermorelin
| Attribute | Ipamorelin | CJC-1295 (no DAC) | Sermorelin |
|---|---|---|---|
| Mechanism | GHRP — ghrelin receptor agonist | GHRH analog — GHRH receptor agonist | GHRH analog — 29-aa fragment of GHRH |
| Half-life | ~2 hours | ~30 minutes | 10–20 minutes |
| FDA regulatory status | Never approved; removed from Cat 2 Sep 2024 | Never approved; removed from Cat 2 Sep 2024 | Formerly approved as Geref; never in Cat 2 |
| Compoundable today? | Yes — 503A | Yes — 503A | Yes — 503A |
| Common dosing | 200–300 mcg SC, 1–3× daily | 100–200 mcg SC, 1–2× daily | 200–500 mcg SC, once daily (evening) |
| Commonly stacked with | CJC-1295 | Ipamorelin | Standalone or with ipamorelin |
| Primary clinical uses | Body composition, recovery, sleep quality | GH pulse amplification, recovery | Anti-aging, sleep quality, body composition |
The patient queries to target
Search demand for ipamorelin and CJC-1295 is substantial and underserved by clinical content. Patients searching these terms are actively looking for a physician-supervised pathway:
- "ipamorelin side effects"
- "CJC-1295 ipamorelin protocol"
- "is ipamorelin legal"
- "ipamorelin dosing"
- "CJC-1295 with or without DAC"
- "ipamorelin results how long"
- "ipamorelin vs sermorelin"
- "CJC-1295 ipamorelin clinic near me"
- "growth hormone secretagogue therapy [city]"
The "is ipamorelin legal" and "CJC-1295 legal status" queries are particularly valuable. Patients asking about legality are highly motivated and looking for confirmation that they can access these compounds through a clinical pathway. A page that answers this question accurately — yes, legally compoundable since September 2024 — and then explains how to access them through your clinic converts this high-intent audience efficiently. Most of the content that currently ranks for these queries comes from gray-market vendors, not clinical practices. That is a gap.
Frequently Asked Questions
Is ipamorelin legally available from a US compounding pharmacy in 2026?
Yes. Ipamorelin was removed from the FDA's Category 2 restricted compounding list in September 2024, returning it to a status where licensed 503A compounding pharmacies can produce it under physician prescription. No waiting for the July 2026 PCAC meeting is required — ipamorelin can be legally compounded and prescribed today.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 without DAC (Modified GRF 1-29) has a half-life of approximately 30 minutes and was removed from the FDA's Category 2 list in September 2024, making it legally compoundable today. CJC-1295 with DAC uses a drug affinity complex that binds to albumin, extending the half-life to 6 to 8 days and allowing less frequent dosing. These are chemically distinct compounds with different regulatory histories and dosing protocols. Confirm with your compounding pharmacy which version they provide before making any marketing claims about protocol frequency or dosing.
Why is ipamorelin stacked with CJC-1295?
Ipamorelin and CJC-1295 work through complementary mechanisms. CJC-1295 acts on the GHRH receptor, stimulating GH release through the same pathway as the body's natural growth hormone-releasing hormone. Ipamorelin acts on the ghrelin receptor, amplifying the pituitary GH response via a separate signaling pathway. Together they produce a more substantial and sustained GH pulse than either compound alone — which is why the combination is more commonly used in clinical longevity practice than either peptide in isolation.
How long does it take for ipamorelin and CJC-1295 to work?
Growth hormone levels on lab testing may increase measurably within 4 to 6 weeks of consistent use. Subjective improvements in sleep quality are often among the earliest patient-reported benefits, typically within 2 to 4 weeks. Body composition changes — increased lean mass, reduction in fat mass — become measurable at 3 to 6 months of consistent protocol adherence. IGF-1 levels, which reflect cumulative GH activity over time, are a commonly tracked biomarker with results typically visible at the 8 to 12-week mark.
Can a longevity clinic advertise ipamorelin by name on Google?
With LegitScript Healthcare certification, yes. Ipamorelin is legally compoundable under physician prescription, making it eligible for certified prescription drug service advertising on Google. Without certification, clinics should use benefit-oriented ad copy — "growth hormone optimization," "GH secretagogue protocols" — and drive patients to educational content that explains the specific compounds and how to access them through a consultation. LegitScript certification typically takes 4 to 8 weeks and costs $1,000 to $4,000 for the initial application.
Is ipamorelin on the WADA banned list?
Yes. Ipamorelin is listed as a prohibited substance under the World Anti-Doping Agency's 2025 Prohibited List under the Growth Hormone Releasing Peptides category. Clinics marketing to competitive athletes subject to WADA testing should disclose this clearly and advise patients to verify their specific sport's rules before beginning any protocol. For recreational athletes and fitness enthusiasts without competitive obligations, this restriction does not apply to their participation.